Explore Rectovaginal Fistula market Growth in 2020-2026
SummaryThe global Rectovaginal Fistula market was valued at USD 835.17 million in 2019 and is expected to reach USD 1342.48 million by the year 2025, at a CAGR of 8.36%.
A rectovaginal fistula is an abnormal connection between the lower portion of your large intestine — your rectum — and your vagina. Bowel contents can leak through the fistula, allowing gas or stool to pass through your vagina. One of the main causes of the rectovaginal fistula is childbirth.
The global Rectovaginal Fistula market was valued at USD 835.17 million in 2019 and is expected to reach USD 1342.48 million by the year 2025, at a CAGR of 8.36%.
The major factors promoting the growth of the rectovaginal fistula market include growing R&D budgets by both governments as well as commercial pharmaceutical and biotechnological companies. The Rectovaginal Fistula market is expected to show high demand and growth in CAGR due to the high rate of prolonged labor observed in the developing nations of Asia-Pacific like India, China, and Japan.
Major Key Players Considered in the Market
- Cook Medical
- Johnson & Johnson Services Inc.
- Pfizer Inc.
- AbbVie Inc.
- Novartis International AG
- Bayer AG
- Bristol-Myers Squibb
- Hoffman La Roche
- Boehringer Ingelheim GmbH
- Eli Lilly and Company
- GlaxoSmithKline plc
- Sanofi S.A.
- and Others.
By Diagnosis, the market is segmented into
- Physical exam,
- contrast test,
- blue dye test,
- CT scan,
- Anorectal Ultrasound
- Anorectal manometry.
Based on treatment type, the Rectovaginal Fistula market has been segmented into
Regions and Countries Level Analysis:
- North America (U.S., Canada, Mexico)
- Europe (Germany, U.K., France, Italy, Russia, Spain etc.)
- Asia-Pacific (China, India, Japan, Southeast Asia etc.)
- South America (Brazil, Argentina etc.)
- Middle East & Africa (Saudi Arabia, South Africa etc.)
The Americas is going to lead the global rectovaginal fistula market owing to the high income of people, and the presence of major market players.
Europe is holding the second position in this market. The market growth in this region is due to the presence of a strong research base and availability of funding for research in the European countries.
The Asia-Pacific region is going to be the fastest-growing region owing to increasing government focus on the biotechnology and the pharmaceutical sector.